Navigation Links
Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
Date:4/30/2013

SAN DIEGO, Calif. and OXFORD, England, April 30, 2013 /PRNewswire/ -- Glide Pharma® today announced the award of a sub-contract from Pfenex Inc. to develop a solid formulation containing the recombinant Protective Antigen (rPA) from Bacillus anthracis expressed in Pfenex Expression Technology™ suitable for delivery with the Glide SDI® (solid dose injector).  This approach will address two important logistical constraints of the currently available vaccine, namely, long term stability during storage and ease of administration.

The Pfenex project has been funded in whole with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201200033C.

Under an existing Biomedical Advanced Research and Development Authority (BARDA) contract, Pfenex has successfully developed a novel rPA that is highly immunogenic and protective in animal studies, with a scalable production process and robust yields.

"Glide Pharma is pleased to be working with Pfenex on this contract from NIAID.  We believe that a combination of Pfenex's proprietary rPA-based anthrax vaccine and Glide Pharma's novel formulations and delivery technology will provide a product suitable in response to an anthrax biothreat," stated Dr Mark Carnegie-Brown , CEO, Glide Pharma.

"We are pleased to award this sub-contract to Glide Pharma. Their novel formulation and delivery technology allows us to expand our anthrax vaccine program," stated Bertrand C. Liang , CEO, Pfenex. "Leveraging the Glide SDI® technology to develop an alternative delivery method of the Pfenex anthrax vaccine further supports our efforts to provide a safe, feasible and cost-effective solution to the United States government's quest to stockpile sufficient vaccine doses to rapidly respond to an anthrax biothreat."

For more information please visit http://www.pfenex.com/news/details/32

About Pfenex Inc.
Pfenex Inc. is a biotechnology company developing biosimilars and innovative vaccines to address unmet and growing global healthcare needs.  Utilizing the company's core technology, Pfenex Expression Technology™ for recombinant protein expression, Pfenex is able to rapidly develop and produce high quality therapeutics. In addition, Pfenex also produces and markets research proteins and reagent proteins for the research and drug development community through its Reagent Proteins division.  For more information please visit www.pfenex.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Nominierungen für BRAVE Awards werden ab jetzt entgegengenommen
2. BRAVE Awards Now Accepting Nominations
3. Bio-IT World Announces Best of Show Awards Finalists for the Bio-IT World Conference & Expo
4. Elsevier and the Belarus Ministry of Education Honor Researchers with Scopus Awards
5. American Federation for Aging Research Announces Recipients of Irving S. Wright and Vincent Cristofalo Scientific Awards
6. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
7. USP Global Fellowship Awards Program Call for Applications
8. 2012-2013 Michael E. DeBakey Journalism Awards Call for Entries
9. Indigo Biosystems Nominated for Two TechPoint Mira Awards for Technology Excellence and Innovation
10. TriLink BioTechnologies Awards Keck Science Department ResearchReward
11. Young Pathologists Receive Awards for Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... JOHNSTON, Iowa (PRWEB) , ... October 12, 2017 ... ... company based in Vilnius, Lithuania, announced today that they have entered into a ... collaboration is to provide CRISPR researchers with additional tools for gene editing across ...
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by Solution ... Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to 2022", ... 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at a ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):